美股异动|诺华制药重挫超13%创1月以来新低,三项临床项目接连受挫

格隆汇
Sep 08
诺华制药(NVS.US)重挫超13%,报138.88美元,创今年1月以来新低。 消息面上,一周之内,诺华制药三项临床项目接连受挫。最新公布的肌肉萎缩症候选药物del-desiran三期试验宣告失败,此前心血管药物pelacarsen三期试验未能降低心血管事件风险,实验性细胞疗法rap-cel则因三名患者死亡而暂停八项临床试验。(格隆汇)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10